Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 10, 2015 - Issue
Submit an article Journal homepage
56
Views
2
CrossRef citations to date
0
Altmetric
Methodology

The EFFECT trial: evaluating exacerbations, biomarkers, and safety outcomes with two dose levels of fluticasone propionate/formoterol in COPD

Alberto Papi1 Department of Internal and CardioRespiratory Medicine, Research Centre on Asthma and COPD, University of Ferrara, Ferrara, ItalyCorrespondence[email protected]
,
Paul W Jones2 Institute for Infection and Immunity, St George’s, University of London, London, UK
,
Prashant S Dalvi3 Medical Science – Respiratory, Mundipharma Research Ltd, Cambridge, UK
,
Kirsten McAulay4 Medical Operations, Mundipharma Research Ltd, Cambridge, UK
,
Tammy McIver5 Data Management and Statistics, Mundipharma Research Ltd, Cambridge, UK
&
Sanjeeva Dissanayake3 Medical Science – Respiratory, Mundipharma Research Ltd, Cambridge, UK
Pages 2431-2438 | Published online: 09 Nov 2015

Citations (2)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

A Papi, D Dokic, W Tzimas, I Mészáros, A Olech-Cudzik, Z Koroknai, K McAulay, S Mersmann, PS Dalvi & T Overend. (2017) Fluticasone propionate/formoterol for COPD management: a randomized controlled trial. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1961-1971.
Read now

Articles from other publishers (1)

Peter Alter, Claus F. Vogelmeier & Rudolf A. Jörres. (2018) COPD und kardiovaskuläre Komorbiditäten. Pneumo News 10:2, pages 27-31.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.